FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1076-1078 March 9, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Barlogie, B. PubMed Citation

The introduction of melphalan and prednisone for the treatment of multiple myeloma was followed by only minor advances in the management of the disease for almost 20 years.¹ The failure of other agents, alone or in combination, to extend survival beyond three years prompted a new treatment strategy in the early 1980s: myeloablative doses of melphalan supported by an infusion of autologous hematopoietic stem cells. After this approach was found to be superior to conventional chemotherapy for the initial treatment of myeloma, the efficacy of two sequential courses of high-dose therapy, each supported by an infusion of autologous stem cells, . . . [Full Text of this Article]

Source Information

From the Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy.

This article has been cited by other articles:

• Lafaras, C., Mandala, E., Verrou, E., Platogiannis, D., Barbetakis, N., Bischiniotis, T., Zervas, K. (2008). Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Ann Oncol 19: 1765-1769 [Abstract] [Full Text]  
• Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., Pezzoni, G., Allievi, C., Pescalli, N., Cassin, M., di Giovine, S., Nicoli, P., de Feudis, P., Strepponi, I., Roato, I., Ferracini, R., Bussolati, B., Camussi, G., Jones-Bolin, S., Hunter, K., Zhao, H., Neri, A., Palumbo, A., Berkers, C., Ovaa, H., Bernareggi, A., Inghirami, G. (2008). CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111: 2765-2775 [Abstract] [Full Text]  
• Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., Michelucci, R., Tassinari, C. A. (2007). Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 69: 573-581 [Abstract] [Full Text]  
• Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S., Baccarani, M. (2007). Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. JCO 25: 2434-2441 [Abstract] [Full Text]  
• Oyajobi, B. O., Munoz, S., Kakonen, R., Williams, P. J., Gupta, A., Wideman, C. L., Story, B., Grubbs, B., Armstrong, A., Dougall, W. C., Garrett, I. R., Mundy, G. R. (2007). Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Molecular Cancer Therapeutics 6: 1701-1708 [Abstract] [Full Text]  
• Cavo, M. (2007). Nonmyeloablative allotransplantation for myeloma: light and shade. Blood 109: 3134-3135 [Full Text]  
• Berenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B., Yeh, H. S. (2007). A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clin. Cancer Res. 13: 1762-1768 [Abstract] [Full Text]